Risk-Benefit Assessment of Fluticasone Propionate in the Treatment of Asthma and Allergic Rhinitis

References

• Fuller R, Johnson M, Bye A. Fluticasone propionate—an update on preclinical and clinical experience. Respir Med 1995; 89((Suppl A))3–18
   PubMedGoogle Scholar
• Holliday S M, Faulds D, Sorkin E M. Inhaled fluticasone propionate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994; 47((2))318–331
   PubMedGoogle Scholar
• Phillipps G H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84((Suppl A))19–23
   PubMedGoogle Scholar
• Leblanc P, Mink S, Keistinen T, et al. A comparison of fluticasone propionate 400 μg/day in adult asthma. Allergy 1994; 49: 380–385
   PubMed Web of Science ®Google Scholar
• LaForce C, Chervinsky P, Selner J, et al. Onset of action of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1993; 92: 223, (abstract)
   PubMedGoogle Scholar
• Chervinsky P, van As A, Bronsky E A, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94: 676–683
   PubMed Web of Science ®Google Scholar
• Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 μg day-1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with BDP (1000 μg day-1) administered by pressurized inhaler. Respir Med 1993; 57: 609–620
   Google Scholar
• Condemi J, Chervinsky J, Goldstein M, et al. Fluticasone propionate 500 mcg/day is superior to triamcinolone acetonide 800 mcg/day in controlling asthma. Am J Respir Crit Care Med 1996; 153((4))A801, (abstract)
   Google Scholar
• Gross G, Wolfe J D, Noonan M J, et al. Fluticasone propionate 500 mcg/day improves asthma more than triamcinolone acetonide 800 mcg/day. Am J Respir Crit Care Med 1996; 153((4))A340, abstract
   Google Scholar
• Cox F, Goodwin B, Pepsin P, et al. Superior impact of inhaled fluticasone propionate 500mg/day versus triamcinolone acetonide 800mg/day or placebo on asthma-specific quality of life in asthmatics. Am J Respir Crit Care Med 1996; 153((4))A340, (abstract)
   Google Scholar
• Dahl R, Lundback Bo, Malo J. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352–1358
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Demedts M G, Yernault J C, et al. Comparison of long-term safety and efficacy of fluticasone propionate and beclomethasone dipropionate in combination with salmeterol in patients with moderate to severe asthma. Am J Respir Crit Care Med 1995; 151((14))A276, (abstract)
   Google Scholar
• Barnes N C, Marone G, Di Maria G U, et al. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993; 6: 877–884
   PubMed Web of Science ®Google Scholar
• Ayres J G, Bateman E D, Lundback B, Harris T AJ. High-dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur J Respir Dis 1995; 8: 579–586
   Google Scholar
• Noonan M, Chervinsky P, Busse W M. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467–1473
   PubMed Web of Science ®Google Scholar
• MacKenzie C A, Tsanakas J, Tabachnik E, et al. An open study to assess the long-term safety of fluticasone propionate in asthmatic children. Br J Clin Pract 1994; 48((1))15–18
   PubMedGoogle Scholar
• Price J F. Asthma, growth and inhaled corticosteroids. Respir Med 1993; 87((Suppl A))23–26
   PubMedGoogle Scholar
• Gustafsson P, Tsanakas J, Gold M, et al. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled BDP 400 μg/day in mild and moderate asthma. Arch Dis Child 1993; 69: 206–211
   PubMed Web of Science ®Google Scholar
• Larsen J S, deBoisblanc B P, Schaberg A, et al. Magnitude of improvement in FEV1 with fluticasone propionate. Am J Respir Crit Care Med 1994; 149: A214, (abstract)
   PubMedGoogle Scholar
• Sheffer A L, LaForce C, Schoenwetter W, et al. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Earn Pract 1996; 42: 369–375
   Google Scholar
• Condemi J J, et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol 1997; 100((4))467–474
   PubMedGoogle Scholar
• Mahajan P, et al. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. J Asthma 1997; 34((3))227–234
   PubMedGoogle Scholar
• MacKenzie C A, Weinberg E G, Tabachnik E. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr 1993; 152: 856–860
   PubMed Web of Science ®Google Scholar
• Price J F, Weller P H. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study). Respir Med 1995; 89: 363–368
   PubMed Web of Science ®Google Scholar
• Harding S M. The human pharmacology of fluticasone propionate. Respir Med 1990; 84((Suppl A))25–29
   PubMedGoogle Scholar
• Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97: 169–176
   PubMed Web of Science ®Google Scholar
• Hanania N A, Chapman K R, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98: 196–208
   PubMed Web of Science ®Google Scholar
• Padfield P L, Teelucksingh S. Inhaled corticosteroids: the endocrinologist's view. Eur Respir Rev 1993; 3((15))494–500
   Google Scholar
• Corren J, Rachelefsky G, Hochhaus G, et al. A five-way parallel randomized study to compare the safety profile of beclomethasone dipropionate (BDP), budesonide (BUD), flunisolide (FLU), fluticasone propionate (HP), and triamcinolone acetonide (TA) in healthy male volunteers. Chest 1996; 110((4))83S, (abstract)
   Google Scholar
• Grahnen A, Eckernas S A, Brundin R M. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharm 1994; 38: 521–525
   PubMed Web of Science ®Google Scholar
• Grove A, Allam C, McFarlane L C. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharm 1994; 38: 527–532
   PubMedGoogle Scholar
• Lonnebo A, et al. A comparison of the effects on the HPA axis of single and repeated doses of inhaled fluticasone propionate. Am J Respir Crit Care Med 1995; 151((4))A375, (abstract)
   Google Scholar
• Dogterom P, Oosterhuis B, Ebels J T, Jonkman J HG. Inhaled fluticasone propionate induces greater Cortisol suppression compared to budesonide. A dose response study using pressurized metered dose inhalers (PMDI's). Eur Respir J 1995; 8((Suppl 19, abstract))303s
   Google Scholar
• Clark D J, Grove A, Cargill R I. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262–266
   PubMed Web of Science ®Google Scholar
• Fabbri L, Burge P S, Croonenborgh L. Comparison of fluticasone propionate with BDP in moderate to severe asthma treated for one year. Thorax 1993; 48: 817–823
   PubMed Web of Science ®Google Scholar
• Boe J, Bakke P, Rodolen T, et al. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary adrenal (HPA) axis. Eur Respir J 1994; 7: 2179–2184
   PubMedGoogle Scholar
• Laforce C, Goldstein H, Storms W, et al. Comparison of inhaled fluticasone propionate (FP) and flunisolide (FLN) effects on the HPA axis as assessed by 6-hour cosyntropin infusion testing. Eur Respir J 1996; 9((Suppl 23, abstract))163S
   Google Scholar
• Clark D J, Lipworth B J. Adrenal suppression with chronic dosing of fluticasone proprionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52: 55–58
   PubMed Web of Science ®Google Scholar
• Boyd G. Systemic effects of inhaled corticosteroids in asthma: a comparative risk-profile assessment of fluticasone propionate and budesonide. Inphanna Weekly, Adis Intl 1996; 3((Suppl))1–22
   Google Scholar
• The British Guidelines on Asthma Management 1995 Review and Position Statement. Thorax 1997; 52: 1–12
   PubMedGoogle Scholar
• Guidelines for the diagnosis and management of asthma. NIH 1997; 97–4051
   Google Scholar
• Bootsma G P, Dekhuizen P NR, Festen J. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996; 153: 924–930
   PubMed Web of Science ®Google Scholar
• Grove A, et al. Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism. Eur J Clin Pharmacol 1996; 50: 275–277
   PubMedGoogle Scholar
• Storms W. The clinical side effect profile of inhaled corticosteroid: the results of a questionnaire survey of over 200 physicians. Am J Respir Crit Care Med 1997; 155((4))A354, (abstract)
   Google Scholar
• Garbe E, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722–727
   PubMed Web of Science ®Google Scholar
• Cumming R G, Mitchell P, Leeder S R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14
   PubMed Web of Science ®Google Scholar
• Wolthers O D, Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 1993; 68: 673–676
   PubMed Web of Science ®Google Scholar
• Hoekx J, et al. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400mcg per day-1. Eur Respir J 1996; 9: 2263–2272
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S, et al. Short-term knemometry and urine Cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J 1997; 10: 1507–1512
   PubMed Web of Science ®Google Scholar
• Wolthers O D, et al. Knemometry, urine Cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res 1997; 41: 44–50
   PubMed Web of Science ®Google Scholar
• Clark D J, Clark R A, Lipworth B J. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax 1996; 52: 941–943
   Google Scholar
• Kamada A K, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996; 153: 1739–1748
   PubMedGoogle Scholar
• Allen D B, et al. Growth in asthmatic children treated with fluticasone propionate. setting a new standard in study design, In press
   Google Scholar
• Nathan R A. The efficacy of fluticasone propionate aqueous nasal spray in the treatment of allergic rhinitis. Today's Therapeutic Trends 1995; 12: 119–134
   Google Scholar
• Gehanno P, Desfougeres J L. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy 1997; 52: 445–450
   PubMedGoogle Scholar
• Bryson H M, Faulds D. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 1992; 43((5))760–775
   PubMedGoogle Scholar
• Meltzer E O, Orgel H A, Bronsky E A, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990; 86: 221–230
   PubMed Web of Science ®Google Scholar
• van As A, Bronsky E A, Dockhorn R J, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993; 91: 1146–1154
   PubMed Web of Science ®Google Scholar
• Banov C H, Woehler T R, LaForce C F, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 1994; 73: 240–246
   PubMedGoogle Scholar
• Dolovich J, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy 1994; 73: 147–153
   PubMedGoogle Scholar
• van Bavel J, Findlay S R, Hampel F C, et al. Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis. Arch Intern Med 1994; 154: 2699–2704
   PubMed Web of Science ®Google Scholar
• Kozma C M, Schulz R M, Sclar D A. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther 1996; 18((2))334–346
   PubMedGoogle Scholar
• Boner A, et al. A double-blind comparison of fluticasone propionate aqueous nasal spray (FPANS) 100 meg given once daily, FPANS 200 meg given once daily and placebo aqueous nasal spray given once daily in the treatment of seasonal allergic rhinitis in children aged 4–11 years. Eur J Allergy Clin Immunol 1992; 47((12))47, (Suppl, abstract)
   Google Scholar
• Bousquet J, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. Allergy 1993; 48: 327–333
   PubMedGoogle Scholar
• Storms W W. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: review of comparator studies. Allergy 1995; 50((Suppl 23))25–29
   PubMedGoogle Scholar
• Howarth P H, Holmberg K, Johnson M. Nasal inflammation—the effects of fluticasone propionate. Allergy 1995; 50((Suppl))1–29
   Google Scholar
• Scadding G, Lund V, Jacques L A. A placebo controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and nonallergic rhinitis. Clin Exp Allergy 1995; 25: 737–743
   PubMed Web of Science ®Google Scholar
• Haye R, Gomez E G. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology 1993; 31: 169–174
   PubMedGoogle Scholar
• Lund V, et al. A placebo-controlled study of fluticasone propionate and beclomethasone dipropionate in seasonal rhinitis. Clin Exp Allergy 1990; 20((1))102, abstract P254
   Google Scholar
• van Bavel J, et al. Intranasal fluticasone propionate once daily is more effective than terfenadine twice daily in relieving symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 1992; 89: 302, (abstract 630)
   Google Scholar
• Darnell R, et al. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy 1994; 24: 1144–1150
   PubMed Web of Science ®Google Scholar
• Vervloet D, Charpin D, Desfougeres J L. Fluticasone propionate aqueous nasal spray versus cetirizine in seasonal rhinitis. J Allergy Clin Immunol 1992; 89: 304, (abstract)
   Google Scholar
• LaForce C F, Dockhorn R J, Findlay S R. Fluticasone propionate: An effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 1994; 38: 145–152
   PubMedGoogle Scholar
• Jordana G, Dolovich J, Briscoe M P. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 588–595
   PubMed Web of Science ®Google Scholar
• Milton D M, Richards D H. Fluticasone propionate— a new and effective treatment for perennial rhinitis in children aged 4–11 years. J Allergy Clin Immunol 1993; 92: 260, (abstract)
   Google Scholar
• van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 1991; 67: 156–162
   PubMedGoogle Scholar
• Lozewicz S, et al. Topical glucocorticoids inhibit activation by allergen in the upper respiratory tract. J Allergy Clin Immunol 1992; 89: 951–957
   PubMedGoogle Scholar
• Rak S, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994; 24: 930–939
   PubMed Web of Science ®Google Scholar
• Juliusson S, et al. Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid. Clin Exp Allergy 1993; 23: 591–599
   PubMedGoogle Scholar
• Peroni D, et al. Fluticasone propionate aqueous nasal spray alleviates the symptoms of perennial allergic rhinitis without changing the mucosal inflammatory cell profile. J Allergy Clin Immunol 1993; 91: 260, (abstract)
   Google Scholar
• Braat J, Ainge G, Rijntjes E. Lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light-and-electron microscopy study. Clin Exp Allergy 1995; 25((10))957–965
   PubMedGoogle Scholar
• Howland W, Field E, Harding S, et al. Fluticasone propionate aqueous nasal spray is an antirhinitic with topical but not systemic activity. Clin Exp Allergy 1996; 26((Suppl 3))18–22
   PubMedGoogle Scholar
• Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994; 225: 628–634
   Google Scholar
• Grossman J, Banov C, Bronsky E A, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993; 92: 594–599
   PubMed Web of Science ®Google Scholar
• Vargas R, McMahon F G, Dockhorn R, et al. An assessment of HPA axis effects of fluticasone propionate aqueous nasal spray using 6-hour ACTH infusion. Clin Pharm Ther 1994; 55((2))184, (abstract)
   Google Scholar
• Haye R, Gomez E G. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with BDP aqueous nasal spray in the treatment of perennial rhinitis. Rhinology 1993; 32: 169–174
   Google Scholar
• Ratner P H, Paull B R, Findlay S R, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as BDP given twice daily. J Allergy Clin Immunol 1992; 90: 285–291
   PubMedGoogle Scholar
• Nathan R A, Bronsky E A, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991; 67: 332–338
   PubMedGoogle Scholar
• Munk Z M, Pearlman D, Graft E, et al. Intranasal fluticasone propionate is effective and well-tolerated in adolescents with seasonal allergic rhinitis. Ped Asthma, Allergy Immunol 1994; 8: 39–46
   Google Scholar
• Lipworth B J. Airway and systemic effects of inhaled corticosteroids asthma: Dose response relationship. Pulm Pharmacol 1996; 9: 19–27
   PubMedGoogle Scholar